vs

Side-by-side financial comparison of Astrana Health, Inc. (ASTH) and FRANKLIN ELECTRIC CO INC (FELE). Click either name above to swap in a different company.

Astrana Health, Inc. is the larger business by last-quarter revenue ($950.5M vs $500.4M, roughly 1.9× FRANKLIN ELECTRIC CO INC). FRANKLIN ELECTRIC CO INC runs the higher net margin — 6.9% vs 0.7%, a 6.2% gap on every dollar of revenue. On growth, Astrana Health, Inc. posted the faster year-over-year revenue change (42.9% vs 9.9%). Over the past eight quarters, Astrana Health, Inc.'s revenue compounded faster (53.3% CAGR vs -4.0%).

Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.

Franklin Electric Co., Inc. is a manufacturer and distributor of products and systems focused on the movement and management of water and energy. The company offers pumps, motors, drives, and controls for use in a variety of residential, commercial, agricultural, industrial, and municipal applications. Headquartered in Fort Wayne, Indiana, the company also operates manufacturing facilities in the United States, Germany, Czech Republic, Italy, Turkey, Mexico, Brazil, Australia, South Africa, C...

ASTH vs FELE — Head-to-Head

Bigger by revenue
ASTH
ASTH
1.9× larger
ASTH
$950.5M
$500.4M
FELE
Growing faster (revenue YoY)
ASTH
ASTH
+33.0% gap
ASTH
42.9%
9.9%
FELE
Higher net margin
FELE
FELE
6.2% more per $
FELE
6.9%
0.7%
ASTH
Faster 2-yr revenue CAGR
ASTH
ASTH
Annualised
ASTH
53.3%
-4.0%
FELE

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ASTH
ASTH
FELE
FELE
Revenue
$950.5M
$500.4M
Net Profit
$6.6M
$34.7M
Gross Margin
35.0%
Operating Margin
1.9%
9.6%
Net Margin
0.7%
6.9%
Revenue YoY
42.9%
9.9%
Net Profit YoY
184.4%
10.6%
EPS (diluted)
$0.12
$0.77

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASTH
ASTH
FELE
FELE
Q1 26
$500.4M
Q4 25
$950.5M
$506.9M
Q3 25
$956.0M
$581.7M
Q2 25
$654.8M
$587.4M
Q1 25
$620.4M
$455.2M
Q4 24
$665.2M
$485.7M
Q3 24
$478.7M
$531.4M
Q2 24
$486.3M
$543.3M
Net Profit
ASTH
ASTH
FELE
FELE
Q1 26
$34.7M
Q4 25
$6.6M
$39.3M
Q3 25
$373.0K
$16.7M
Q2 25
$9.4M
$60.1M
Q1 25
$6.7M
$31.0M
Q4 24
$-7.8M
$33.7M
Q3 24
$16.1M
$54.6M
Q2 24
$19.2M
$59.1M
Gross Margin
ASTH
ASTH
FELE
FELE
Q1 26
35.0%
Q4 25
33.8%
Q3 25
35.9%
Q2 25
36.1%
Q1 25
36.0%
Q4 24
33.8%
Q3 24
35.7%
Q2 24
36.8%
Operating Margin
ASTH
ASTH
FELE
FELE
Q1 26
9.6%
Q4 25
1.9%
10.2%
Q3 25
2.0%
14.6%
Q2 25
3.1%
15.0%
Q1 25
3.3%
9.7%
Q4 24
0.1%
8.9%
Q3 24
5.9%
13.8%
Q2 24
6.2%
14.6%
Net Margin
ASTH
ASTH
FELE
FELE
Q1 26
6.9%
Q4 25
0.7%
7.7%
Q3 25
0.0%
2.9%
Q2 25
1.4%
10.2%
Q1 25
1.1%
6.8%
Q4 24
-1.2%
6.9%
Q3 24
3.4%
10.3%
Q2 24
3.9%
10.9%
EPS (diluted)
ASTH
ASTH
FELE
FELE
Q1 26
$0.77
Q4 25
$0.12
$0.87
Q3 25
$0.01
$0.37
Q2 25
$0.19
$1.31
Q1 25
$0.14
$0.67
Q4 24
$-0.14
$0.73
Q3 24
$0.33
$1.17
Q2 24
$0.40
$1.26

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASTH
ASTH
FELE
FELE
Cash + ST InvestmentsLiquidity on hand
$429.5M
$80.4M
Total DebtLower is stronger
$134.4M
Stockholders' EquityBook value
$779.3M
$1.3B
Total Assets
$2.2B
$2.0B
Debt / EquityLower = less leverage
0.10×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASTH
ASTH
FELE
FELE
Q1 26
$80.4M
Q4 25
$429.5M
$99.7M
Q3 25
$463.4M
$102.9M
Q2 25
$342.1M
$104.6M
Q1 25
$260.9M
$84.0M
Q4 24
$290.8M
$220.5M
Q3 24
$350.3M
$106.3M
Q2 24
$327.7M
$58.1M
Total Debt
ASTH
ASTH
FELE
FELE
Q1 26
$134.4M
Q4 25
$135.2M
Q3 25
$135.2M
Q2 25
$14.5M
Q1 25
$14.9M
Q4 24
$11.6M
Q3 24
$11.6M
Q2 24
$87.2M
Stockholders' Equity
ASTH
ASTH
FELE
FELE
Q1 26
$1.3B
Q4 25
$779.3M
$1.3B
Q3 25
$775.5M
$1.3B
Q2 25
$765.5M
$1.3B
Q1 25
$745.4M
$1.3B
Q4 24
$712.7M
$1.3B
Q3 24
$704.6M
$1.3B
Q2 24
$678.9M
$1.2B
Total Assets
ASTH
ASTH
FELE
FELE
Q1 26
$2.0B
Q4 25
$2.2B
$1.9B
Q3 25
$2.2B
$2.0B
Q2 25
$1.4B
$2.0B
Q1 25
$1.3B
$1.9B
Q4 24
$1.4B
$1.8B
Q3 24
$1.3B
$1.8B
Q2 24
$1.3B
$1.8B
Debt / Equity
ASTH
ASTH
FELE
FELE
Q1 26
0.10×
Q4 25
0.10×
Q3 25
0.10×
Q2 25
0.01×
Q1 25
0.01×
Q4 24
0.01×
Q3 24
0.01×
Q2 24
0.07×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASTH
ASTH
FELE
FELE
Operating Cash FlowLast quarter
$-2.9M
Free Cash FlowOCF − Capex
$-6.0M
FCF MarginFCF / Revenue
-0.6%
Capex IntensityCapex / Revenue
0.3%
Cash ConversionOCF / Net Profit
-0.44×
TTM Free Cash FlowTrailing 4 quarters
$104.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASTH
ASTH
FELE
FELE
Q1 26
Q4 25
$-2.9M
$104.2M
Q3 25
$10.0M
$102.7M
Q2 25
$90.9M
$51.5M
Q1 25
$16.6M
$-19.5M
Q4 24
$-10.9M
$110.3M
Q3 24
$34.0M
$116.1M
Q2 24
$23.2M
$36.4M
Free Cash Flow
ASTH
ASTH
FELE
FELE
Q1 26
Q4 25
$-6.0M
$88.7M
Q3 25
$7.4M
$91.3M
Q2 25
$89.5M
$39.9M
Q1 25
$13.6M
$-26.3M
Q4 24
$-13.5M
$97.5M
Q3 24
$31.7M
$106.6M
Q2 24
$20.4M
$26.1M
FCF Margin
ASTH
ASTH
FELE
FELE
Q1 26
Q4 25
-0.6%
17.5%
Q3 25
0.8%
15.7%
Q2 25
13.7%
6.8%
Q1 25
2.2%
-5.8%
Q4 24
-2.0%
20.1%
Q3 24
6.6%
20.1%
Q2 24
4.2%
4.8%
Capex Intensity
ASTH
ASTH
FELE
FELE
Q1 26
Q4 25
0.3%
3.1%
Q3 25
0.3%
2.0%
Q2 25
0.2%
2.0%
Q1 25
0.5%
1.5%
Q4 24
0.4%
2.6%
Q3 24
0.5%
1.8%
Q2 24
0.6%
1.9%
Cash Conversion
ASTH
ASTH
FELE
FELE
Q1 26
Q4 25
-0.44×
2.65×
Q3 25
26.69×
6.14×
Q2 25
9.65×
0.86×
Q1 25
2.48×
-0.63×
Q4 24
3.28×
Q3 24
2.11×
2.13×
Q2 24
1.21×
0.62×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASTH
ASTH

Medicare$542.4M57%
Commercial$99.1M10%
Care Delivery$92.1M10%
Care Enablement$78.9M8%
Other Third Parties$58.0M6%
Health Care Patient Service$39.8M4%
Health Care Other$25.5M3%
Other$12.1M1%
Management Service$10.3M1%

FELE
FELE

Segment breakdown not available.

Related Comparisons